VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
LSTA
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
LSTALisata Therapeutics, Inc.
$1.04$9M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksLSTACash Flow

Lisata Therapeutics, Inc. (LSTA) Cash Flow Statement

30Y historyFree accessUpdated daily

Free cash flow remains deeply negative with quarterly outflows reaching as high as $7.0 million, indicating a high-intensity burn rate that is only partially mitigated by stock-based compensation.

Income StatementBalance SheetCash FlowRatios

LSTA Cash Flow Statement

Annual statement

LSTA Cash Flow Statement

Lisata Therapeutics, Inc. (LSTA) cash flow statement — 30-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Mar'97Mar'96Mar'95
Cash from Operations-21.66M-15.95M-19.36M-20.03M-21.17M-22.25M-8.82M-18.88M-19.99M-20.88M-23.67M-39.26M-46.9M-27.1M-13.85M-20.93M-8.48M-8.65M-4.73M-6.13M-3.64M-834K-1.46M-1.02M1.01M-373.84K-1.98M-364.12K-304.27K-838.44K-840K
Operating CF Margin %--9381.76%-1935.6%--------67.08%-174.57%-261.42%-184.75%-96.67%-208.24%-12.14%-74.78%-5664.48%-2647.12%-7958.25%-2365.14%-3005.81%-1581.13%1235.9%-347.93%-371.59%-2832.71%---3.99%
Operating CF Growth %-175.23%17.6%3.37%5.38%4.83%-152.13%53.27%5.52%4.26%11.8%39.71%16.29%-73.03%-95.64%33.81%-146.89%1.98%-82.75%22.83%-68.53%-336.31%42.86%-42.84%-201.64%368.93%81.08%-442.67%-19.67%63.71%0.19%-278.72%
Net Income-17.16M-16.59M-19.98M-20.84M-54.23M-27.47M-8.14M-19.35M-16.17M-16.17M-33.31M-81.01M-55.47M-39.49M-36.1M-34.57M-19.4M-24.18M-9.24M-10.45M-6.05M-1.75M-1.75M-1.04M-1.16M-2.03M-2.03M-1.11M-268.96K3.04K-3.37M
Depreciation & Amortization24K146K174K189K69K55K63K65K225K372K450.27K2.69M2.19M1.61M1.55M1.44M5.14M577.04K115.96K53.78K240.12K7.84K13.54K64616.77K155.44K155.64K82.34K3881.75K460K
Stock-Based Compensation1.35M1.23M1.65M2.04M2.64M2M1.26M1.29M2.45M1.96M2.6M9.75K11.21K6.84M6.71K10.27M7.86M12.32M3.89M4.59M00000000000
Deferred Taxes-6.03M00000000-12.1M138.04K-17.24M-104.2K780.1K-175.53K-688.7K-830.68K021.5K000000000000
Other Non-Cash Items663K552K-325K-957K31.18M2.51M307K232K-1.15M-86.29K2.88M-8.51M8.13M1.59M12.74M3.55M1.75M-90.22K6.95K21.24K2.3M376.05K220.34K324.59K297.89K589.56K591.34K356.52K9K-592.05K-1.43M
Working Capital Changes-519K-1.29M-873K-462K-831K647K-2.32M-1.12M-5.35M5.15M3.56M2.45M-1.66M1.57M3.07M-926.39K-3M2.73M475.08K-352.22K-126.2K527.15K54.83K-303K1.85M914.19K-695.78K309.36K-44.7K-251.18K3.5M
Change in Receivables3K401K-900K000000-95.69K-325.62K545.17K-1.2M-573K-554.88K-443.13K98.5K571.69K-4.09K00000000000-100K
Change in Inventory000000000-571.61K269.07K1.16M-2.15M-157.2K-465.28K-647.75K-7.47M-2.43M0000000000000
Change in Payables-1.92M-2.57M-995K88K-223K1.25M-2.84M-1.86M-5.9M5.67M-48.7K79.26K469.82K2.92M1.68M-837.18K4.5M2.83M000000000000-1.8M
Cash from Investing72.92M15.09M13.23M10.1M28.91M-54.9M-7.28M21.43M-4.71M41.27M-2.85M3.8M-10.74M-2.69M6.09M-2.05M-17.11M-1.69M-9.79K153.11K-43.14K0-3.29K847.42K-1.25M362.94K-374.61K-2.55M0-5.93K-380K
Capital Expenditures0-28K00-285K-60K-20K0-134K-135.28K-2.85M-3.19M-3.66M-2.69M-531.32K-574.86K-16.38M-2.39M-9.79K-117.89K-43.14K0-3.29K-2.58K-1.13K-9.06K-25.29K-442.16K0-8.93K-440K
CapEx % of Revenue0%16.47%--------8.08%14.17%20.39%18.35%3.71%5.72%23.46%20.64%11.71%50.89%94.34%-6.77%3.99%1.39%8.43%4.75%3439.84%--2.09%
Acquisitions72.92M0-130K0-3.32M54.84K7.26K02.55M67.88M0050.89K012.28M320.86K0696.46K0271K00000000000
Investments-------------------------------
Other Investing00000-54.84K-7.26K02.55M-188.79K-1.75M6.98K-7.13K0-5.66M2.6K-1.05M000000850K-1.25M372K-817.26K30003K60K
Cash from Financing212.48M599K-206K385K-224K85.28M18.58M1.18M824K-931.77K20.9M36.6M30.67M62.19M8.74M20.07M33.86M17.07M2.87M7.85M3.63M1.29M1.28M366.19K209.95K-23.43K1.18M4.34M317.37K844.34K960K
Debt Issued (Net)00000000-159K-6.21M-9.58M133.03K12.49M336.42K29.44K2.45M869.49K2.36M-30.13K-92.42K56.69K423K165.49K252.41K103.95K-23.43K-23.46K84.59K-400K317.37K0
Equity Issued (Net)212.85M852K68K321K43K85.5M18.73M1.31M1.03M5.7M11.56M36.47M16.71M58.74M11.03M20.5M30.11M15.67M2.9M7.94M3.57M872K1.11M219.78K001.21M4.25M1.79M0844.34K
Dividends Paid0000000000-15M000-327.75K0-222.92K00000000000000
Share Repurchases00000000000000-5.39M-650K000000000000000
Other Financing-375K-253K-274K64K-267K-224K-148K-130K-48K-419K18.92M01.47M3.12M-1.99M-2.88M3.1M-959.89K00000-106K106K0000526.97K115.66K
Net Change in Cash263.72M-253K-6.38M-9.56M7.51M8.13M2.48M3.73M-23.87M19.46M-5.61M1.14M-26.96M32.4M992.02K-2.87M8.45M6.73M-1.87M1.87M-52.21K461K-183.08K191.69K-32.01K-34.34K-1.17M1.43M13.1K-34-270K
Free Cash Flow-21.66M-15.98M-19.36M-20.03M-21.45M-22.3M-8.84M-18.88M-20.12M-21.01M-26.52M-42.44M-50.55M-29.79M-14.38M-21.5M-24.85M-11.04M-4.74M-6.25M-3.68M-834K-1.46M-1.02M1M-382.9K-2M-806.27K-304.27K-847.37K-1.28M
FCF Margin %-21662%-9398.24%-1935.6%--------75.15%-188.74%-281.8%-203.1%-100.38%-213.96%-35.6%-95.42%-5676.19%-2698.01%-8052.59%-2365.14%-3012.58%-1585.12%1234.5%-356.37%-376.35%-6272.55%---6.08%
FCF Growth %-25.33%17.46%3.37%6.63%3.81%-152.23%53.17%6.15%4.24%20.76%37.52%16.04%-69.68%-107.13%33.11%13.48%-125.22%-132.72%24.13%-69.75%-341.49%42.99%-42.8%-202.02%362.27%80.87%-148.21%-164.99%64.09%33.8%-4166.67%
FCF per Share-2.33-1.84-2.32-2.48-4.14-6.05-8.59-27.43-31.15-35.14-60.74-131.25-231.50-218.04-155.87-364.05-722.07-1271.53-1174.62-2855.33-2658.46-2513.26-6743.35-5854.256739.89-2587.19-13521.93-9714.14-19016.81-52960.63-5311.20
FCF Conversion (FCF/Net Income)1.26x0.96x0.97x0.96x0.39x0.81x1.08x0.94x1.24x-0.91x0.72x0.49x0.85x0.70x0.25x0.44x0.36x0.33x0.51x0.59x0.60x0.48x0.83x0.98x-0.87x0.18x0.97x0.33x0.91x-0.49x0.25x
Interest Paid000000000000001.77M1.52M279.6K00000000000000
Taxes Paid000000000000002.1M1.12M2.06M00000000000000

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Clinical trial funding shortfall

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Operating Cash Flow Deficit Persistence

According to quarterly financial statements, Lisata's operating cash flow consistently tracks below net income, with OCF/NI ratios fluctuating between 0.51 and 1.30, suggesting that the company's cash burn is driven primarily by core R&D activities rather than significant non-cash accruals or accounting adjustments.

The lack of a stable relationship between net income and operating cash flow reflects the volatility inherent in clinical-stage biotech operations. Investors should monitor these fluctuations as they indicate that cash outflows are highly sensitive to the timing of clinical trial milestones and associated vendor payments.

Persistent Free Cash Flow Erosion

As reported in recent filings, Lisata's free cash flow remains deeply negative, with quarterly outflows ranging from $2.5 million to $7.0 million, confirming that the company is currently in a capital-intensive phase with no internal cash generation to offset its research expenditures.

The consistent negative trajectory of free cash flow underscores the company's total dependence on external financing to maintain its pipeline. This trend appears unlikely to reverse until the company achieves a major clinical readout or secures a strategic partnership that provides non-dilutive capital.

Working Capital Volatility Impacts Liquidity

Based on the provided cash flow data, working capital changes have been highly erratic, swinging from a $2.1 million inflow in 2024Q3 to a $2.1 million outflow in 2024Q1, which suggests that management's cash management is heavily influenced by the timing of clinical trial payables.

This volatility in working capital may indicate that the company is managing its cash runway by delaying or accelerating payments to clinical research organizations. Such practices warrant further investigation as they may mask the true underlying rate of operational cash consumption.

Stock-Based Compensation Obscures Burn

Analysis of the cash flow statement reveals that stock-based compensation, which peaked at $871,800 in 2024Q4, serves as a significant non-cash expense that effectively subsidizes the company's operating losses, thereby masking the true economic cost of talent retention during this pre-revenue phase.

While SBC preserves cash, it represents a hidden cost to shareholders through ongoing dilution. Investors should consider the impact of this equity-based compensation on their ownership stake when evaluating the company's long-term capital requirements.

LSTA — Frequently Asked Questions

Quick answers to the most common questions about buying LSTA stock.

How much cash does Lisata Therapeutics, Inc. (LSTA) generate from operations?

Lisata Therapeutics, Inc. (LSTA) generated $-15.9M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Lisata Therapeutics, Inc.'s free cash flow?

Lisata Therapeutics, Inc. (LSTA) reported negative free cash flow of $16.0M in 2025, indicating capital requirements exceeded cash from operations.

What is Lisata Therapeutics, Inc.'s capital expenditure (CapEx)?

Lisata Therapeutics, Inc. (LSTA) spent $0.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.